FDA nanotechnology task force
This article was originally published in The Gray Sheet
Executive Summary
Newly formed task force will assess the agency's readiness to handle a swelling wave of medical nanotechnology, wherein the control of matter at the nano level - one thousand- to one hundred thousand-times smaller than the thickness of a sheet of paper - enables novel applications, according to an Aug. 9 release (1"The Gray Sheet" April 24, 2006, p. 12). The task force will seek to identify gaps in policy and/or institutional knowledge and craft regulatory approaches that encourage the continued development of devices that incorporate nanomaterials. A public meeting is scheduled for Oct. 10 to explore such topics as the biological interactions unique to nanotechnology that may lead to either beneficial or adverse health effects...You may also be interested in...
FDA’s Preparedness For Nanotech Debated At Public Meeting
A former FDA deputy commissioner joined other speakers at an Oct. 10 meeting in urging the agency to seek additional expertise and resources in its oversight of products that rely on materials controllable at scales as small as one-billionth of a meter
FDA Inks Nanotech Agreement With Cancer And Standards Institutes
FDA collaboration in the nanotechnology field with two other federal agencies may serve to facilitate premarket reviews for nanotech-based cancer diagnostics and therapeutics
FDA Will Consider Nano-Ingredients At An October Meeting
Medical products manufactured using materials that can be measured and controlled at dimensions one thousand- to one hundred thousand-times smaller than the thickness of a sheet of paper will be the subject of a public meeting FDA is planning for mid-October
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Medtech Insight?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: